Achillion Pharmaceuticals, Inc. (ACHN) Receives Consensus Rating of “Buy” from Brokerages
Shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) have been assigned an average recommendation of “Buy” from the eleven research firms that are currently covering the firm. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $9.75.
A number of brokerages recently weighed in on ACHN. Leerink Swann raised Achillion Pharmaceuticals from a “market perform” rating to an “outperform” rating and raised their price objective for the company from $4.00 to $6.00 in a report on Thursday, May 18th. Zacks Investment Research cut Achillion Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, May 10th. Jefferies Group LLC reissued a “hold” rating on shares of Achillion Pharmaceuticals in a research note on Wednesday, April 26th. Maxim Group reduced their target price on Achillion Pharmaceuticals from $8.00 to $5.00 and set a “buy” rating on the stock in a research note on Tuesday, April 25th. Finally, Robert W. Baird boosted their target price on Achillion Pharmaceuticals from $5.00 to $10.00 and gave the company an “outperform” rating in a research note on Monday, April 24th.
A number of hedge funds have recently bought and sold shares of the stock. Deschutes Portfolio Strategy LLC boosted its stake in shares of Achillion Pharmaceuticals by 13.4% in the first quarter. Deschutes Portfolio Strategy LLC now owns 25,430 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 3,000 shares during the last quarter. Teza Capital Management LLC bought a new stake in shares of Achillion Pharmaceuticals during the first quarter worth approximately $131,000. Whalerock Point Partners LLC bought a new stake in shares of Achillion Pharmaceuticals during the third quarter worth approximately $264,000. Dynamic Technology Lab Private Ltd bought a new stake in shares of Achillion Pharmaceuticals during the first quarter worth approximately $138,000. Finally, Highbridge Capital Management LLC bought a new stake in shares of Achillion Pharmaceuticals during the first quarter worth approximately $149,000. Institutional investors own 77.85% of the company’s stock.
Achillion Pharmaceuticals (NASDAQ:ACHN) opened at 4.15 on Friday. The firm’s 50-day moving average price is $3.75 and its 200 day moving average price is $4.08. The firm’s market cap is $567.40 million. Achillion Pharmaceuticals has a 52 week low of $3.15 and a 52 week high of $10.06.
Achillion Pharmaceuticals (NASDAQ:ACHN) last issued its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.16) by $0.01. During the same period in the prior year, the company posted ($0.13) EPS. Equities analysts forecast that Achillion Pharmaceuticals will post ($0.64) earnings per share for the current fiscal year.
Achillion Pharmaceuticals Company Profile
Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.
Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.